Key facts
- Notable investors include Draper Associates, NZVC, Compagnie d'Investissements et de Gestion Privée, LongGame.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Herasight
- ·The full record, as it builds
Funding rounds
No funding rounds for Herasight are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Herasight
Operator of an advanced embryo screening company intended for prospective parents to assess genetic risk and trait likelihood before implantation. The company's platform integrates ultra-low pass sequencing, family medical history, ancestry-aware polygenic scoring, embryo simulation, and disease trait risk stratification, enabling fertility clinics and IVF patients to make data-driven embryo selection decisions that account for both monogenic and complex condition prediction across diverse genetic backgrounds.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Website
- herasight.com/
- Ownership
- Privately Held (backing)
Herasight doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Herasight shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Herasight in its N-PORT filings yet. We sweep new filings monthly.